Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00449865 · ClinicalTrials.gov registry record · Phase 3
NET-PD LS-1 Creatine in Parkinson's Disease
A Phase 3 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,741
- Enrollment target
NCT00449865 is a Phase 3 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 1,741 participants.
The verdict
NCT00449865, a Phase 3 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,741 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine if the nutritional supplement creatine slows the progression of Parkinson's disease over time.
Interventions
- OTHER placebo
- DRUG creatine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,741 participants |
| Start Date | 2007-03 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00449865
The ClinicalTrials.gov registry entry for NCT00449865 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,741 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00449865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00449865 about?
NCT00449865 is a clinical study titled "NET-PD LS-1 Creatine in Parkinson's Disease". The purpose of this trial is to determine if the nutritional supplement creatine slows the progression of Parkinson's disease over time.
What is the current status of trial NCT00449865?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,741 participants. The study started on 2007-03. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00449865?
The interventions under investigation include: placebo (OTHER), creatine (DRUG).
Who is sponsoring clinical trial NCT00449865?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.